Skip to content

Study of the natural history of patients with rare inherited metabolic diseases, optimal treatment and complications

Study of the natural history of patients with rare inherited metabolic diseases, optimal treatment and complications - Life with an inherited metabolic disease

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON53541
Enrollment
2000
Registered
2023-09-21
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(layman's term not used by patient groups metabolic disease not applicable)

Interventions

None listed

Sponsors

Erasmus MC, Universitair Medisch Centrum Rotterdam
Lead Sponsor

Eligibility

Age
16 Years to 99 Years

Inclusion criteria

Inclusion criteria: (see Protocol C1. page 10-11, paragraph 4.2 Inclusion criteria) - Age >= 16 years. - Written informed consent. - Cases: capacitated and incapacitated patients with a rare inherited metabolic disease, who are in care at UMCs and satellite expert centers. - Controls: healthy siblings and/or unrelated neighbors/ friends/ partners of the patients selected via the cases. List of diagnosis groups based on current patient population in the UMCs: - Urea cycle defects - Disorders of amino acid metabolism - Phenylketonuria - Homocystinuria - Glycogen overloading diseases - Mitochondropathy - Lysosomal overloading diseases - Fatty acid oxidation disorders - Disorders of glycosylation - Galactosemia - Peroxisomal disorders - Congenital hyperinsulinism - Porphyrias - Lipoprotein deficiencies - Disorders of vitamin metabolism - Disorders of glycosylation (CDG) - Rest of rare inherited metabolic diseases

Exclusion criteria

Exclusion criteria: (see Protocol C1. page 11) No signed 'informed consent' present.

Design outcomes

Primary

MeasureTime frame
(also see: C1. Protocol, page 11, paragraph 5.1.1) A metabolic bio-database, with DNA, blood samples, urine samples, faeces samples and hair samples from patients with inherited metabolic diseases, combined with the clinical and physical data.

Secondary

MeasureTime frame
(also see: C1. Protocol, page 11 and 12, paragraph 5.1.2) Clinical data: medication, history and symptoms, radiology data, other medical information such as endoscopies and surgery reports, and ECG. Disease specific or general questionnaires. Physical data: physical disabilities, neurological disorders, anthropometry, blood pressure, eye-hand coordination, activity level and pain level, and fundus.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)